Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 810-842

  Elmeliegy, Mohamed ^a   Lowe, Philip ^b   Krzyzanski, Wojciech ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

compartmental models; monoclonal antibodies; PBPK

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CATABOLISM; COHORT ANALYSIS; COMPARTMENT MODEL; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG TRANSPORT; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PREDICTION; PROCESS DEVELOPMENT; PROCESS MODEL; SPLANCHNIC NERVE; VISCERA; ALGORITHM; BIOLOGICAL MODEL; BLOOD VESSEL; ENDOSOME; LIVER; LUNG; METABOLISM; STATISTICAL MODEL;

ALGORITHMS; ANTIBODIES, MONOCLONAL; BLOOD VESSELS; ENDOSOMES; HUMANS; LIVER; LUNG; MODELS, BIOLOGICAL; MODELS, STATISTICAL;

EID: 84903593655     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9591-x     Document Type: Article

References (23)

1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-87.
2. Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6(4):607-20.
3. Reichert JM. Marketed therapeutic antibodies compendium. MABS. 2012;4(3):413-5.
4. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58.
5. Tang L et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004;93(9):2184-204. (Pubitemid 39129617)
6. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633-59.
7. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67-86.
8. Garzone PD, Atkinson Jr AJ. In search of physiologically based distribution volume estimates for macromolecules. Clin Pharmacol Ther. 2012;92(4):419-21.
9. Brambell FW, Halliday R, Morris IG. Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice. Proc R Soc Lond B Biol Sci. 1958;149(934):1-11.
10. Baxter LT et al. Biodistribution of monoclonal-antibodies-scaleup from mouse to human using a physiologically-based pharmacokinetic model. Cancer Res. 1995;55(20):4611-22.
11. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687-709. (Pubitemid 47477039)
12. Urva SR, Yang VC, Balthasar JP. Development and validation of an enzyme linked immunosorbent assay for the quantification of carcinoembryonic antigen in mouse plasma. J Immunoass Immunochem. 2009;30(4):418-27.
13. Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for highaffinity binding to FcRn. AAPS J. 2012;14(4):850-9.
14. Abuqayyas L, Balthasar JP. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. J Pharmacokinet Pharmacodyn. 2012;39(6):683-710.
15. Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39(6):711-23.
16. Cao Y, Balthasar JP, Jusko WJ Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013
17. Ober RJ et al. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A. 2004;101(30):11076-81. (Pubitemid 38989586)
18. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589-96. (Pubitemid 41355898)
19. Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12(1):33-43.
20. Nestorov IA et al. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm. 1998;26(1):21-46. (Pubitemid 28429460)
21. Laurin J et al. Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants. J Pharmacokinet Biopharm. 1999;27(5):491-512. (Pubitemid 30497280)
22. Krzyzanski W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn. 2011;38(2):179-204.
23. Rudin W. Functional analysis, McGraw-Hill series in higher mathematics. New York: McGraw-Hill; 1973. xiii, 397 p.